Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model

Daptomycin (DAP) is being used more frequently to treat infections caused by vancomycin-resistant enterococcus (VRE). DAP tends to be less active against enterococci than staphylococci and may require high doses or combination therapy to be bactericidal. Fosfomycin (FOF) has activity against VRE and...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Antimicrob Agents Chemother
Glavni autori: Hall Snyder, Ashley D., Werth, Brian J., Nonejuie, Poochit, McRoberts, John P., Pogliano, Joe, Sakoulas, George, Yim, Juwon, Singh, Nivedita, Rybak, Michael J.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2016
Teme:
Experimental Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5038233/
https://ncbi.nlm.nih.gov/pubmed/27431211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00687-16
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items